Analysts at StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Stock Performance
The stock’s 50 day moving average is $11.13 and its 200-day moving average is $12.16. The company has a current ratio of 0.33, a quick ratio of 0.26 and a debt-to-equity ratio of 3.07. The stock has a market cap of $820,000.00, a PE ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a 52-week low of $0.61 and a 52-week high of $24.20.
About Acorda Therapeutics
Further Reading
- Five stocks we like better than Acorda Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- MarketBeat Week in Review – 4/22 – 4/26
- Overbought Stocks Explained: Should You Trade Them?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Where to Find Earnings Call Transcripts
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.